Kraig Biocraft Labs Triples Spider Silk Screening Capacity Amid Project Atlas Breakthroughs
Summary
Kraig Biocraft Laboratories has significantly expanded its research and development capacity, tripling its screening throughput for Project Atlas, its next-generation recombinant spider silk program. This investment in new personnel and advanced equipment is a direct response to rapid progress and breakthroughs in creating new spider silk transgenics, which are now being generated at the highest levels in the company's history. For a development-stage biomaterials company like KBLB, this acceleration in R&D is a material positive, signaling a faster path to identifying and developing advanced materials for potential industrial and defense applications. The increased capacity is expected to shorten development timelines and improve the ability to identify breakthrough material candidates. Investors should monitor future updates on specific product advancements or commercialization efforts as a result of this accelerated R&D.
At the time of this announcement, KBLB was trading at $0.12 on OTC in the Manufacturing sector, with a market capitalization of approximately $125.4M. The 52-week trading range was $0.07 to $0.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.